Boehringer, Yale trial digital tech in heart failurePatients with heart failure often have a dismal prognosis as the condition usually worsens over time, but a Share XBoehringer, Yale trial digital tech in heart failurehttps://pharmaphorum.com/news/boehringer-yale-trial-digital-tech-in-heart-failure/
BI signs schizophrenia app deal with Click TherapeuticsBoehringer Ingelheim has signed a $500 million contract with Click Therapeutics to co-develop and market a digital treatment Share XBI signs schizophrenia app deal with Click Therapeuticshttps://pharmaphorum.com/news/bi-signs-schizophrenia-app-deal-with-click-therapeutics/
AZ trumpets Farxiga survival data in renal disease at ESC 2020AstraZeneca’s Farxiga is already ahead of rivals in the SGLT2 inhibitor field in heart failure, and now looks Share XAZ trumpets Farxiga survival data in renal disease at ESC 2020https://pharmaphorum.com/news/az-trumpets-farxiga-survival-data-in-renal-disease-at-esc-2020/
NHS looks for digital pioneers to reshape services during pandemicA fellowship programme is looking for digital pioneers to design and lead service transformation projects in England’s NHS Share XNHS looks for digital pioneers to reshape services during pandemichttps://pharmaphorum.com/news/nhs-looks-for-digital-pioneers-to-reshape-services-during-pandemic/
Redx shares soar after IPF drug licence deal with AstraZenecaShares in Redx Pharma were soaring this morning after it licensed its preclinical fibrotic disease drug RXC006 to Share XRedx shares soar after IPF drug licence deal with AstraZenecahttps://pharmaphorum.com/news/redx-shares-soar-after-ipf-drug-deal-with-astrazeneca/
Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart failureThe FDA’s approval of AstraZeneca’s SGLT2 inhibitor Farxiga in heart failure was a first for the class, but Share XStudy puts Jardiance in hot pursuit of AZ’s Farxiga in heart failurehttps://pharmaphorum.com/news/study-puts-jardiance-in-hot-pursuit-of-azs-farxiga-in-heart-failure/
Boehringer launches open innovation project for work-at-home scientistsGermany’s Boehringer Ingelheim is to make a bank of its molecules available to scientists in a bid to Share XBoehringer launches open innovation project for work-at-home scientistshttps://pharmaphorum.com/r-d/news-r-d/boehringer-launches-open-innovation-project-for-work-at-home-scientists/
BI opens second branch of digital lab in ChinaBoehringer Ingelheim has announced that it will open a second branch of its digital lab, BI X, in Share XBI opens second branch of digital lab in Chinahttps://pharmaphorum.com/news/bi-opens-branch-of-digital-lab-in-china/
FDA fast-tracks Lilly/Boehringer’s Jardiance in chronic kidney diseaseThe FDA has granted a speedy review of Eli Lilly and Boehringer Ingelheim’s Jardiance for a potential new Share XFDA fast-tracks Lilly/Boehringer’s Jardiance in chronic kidney diseasehttps://pharmaphorum.com/news/fda-fast-tracks-lilly-boehringers-jardiance-in-chronic-kidney-disease/
